Neuroone Medical Technologies is trading 6.56% down at $1.85 after closing at $1.98 on August 27, 2026, with no clear company-specific catalyst identified for the decline.
- Its August 27 announcement described successful large-animal StereoCED procedures and progress toward human investigational studies, which was constructive rather than negative.
- Broader indexes are modestly higher, so marketwide weakness does not clearly explain the move.
- Volume and unusual activity data were unavailable.